Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Parkinson disease in which the cause of the disease is a mutation in the VPS35 gene.
Features include: Resting tremor, Slowness of movement (bradykinesia), Parkinsonism, and Muscle stiffness (rigidity) and 4 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 | Resting tremor, Slowness of movement (bradykinesia), Parkinsonism |
VPS35-related Parkinson disease (PARK-VPS35) should be considered in individuals with the following clinical, imaging, and family history findings. Clinical findings. The clinical manifestations of PARK-VPS35 are similar to those of Parkinson disease of unknown cause representing a simplex case (also referred to as "sporadic" Parkinson disease; see ). However, onset for PARK-VPS35 is on average a decade earlier, progression is slower, and there is a lower risk of atypical signs, neuropsychiatric disturbances, and dementia. The cardinal sign of PARK-VPS35 is parkinsonism, defined as:
No approved treatments are currently available for Parkinson disease 17. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with PARK-VPS35, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with VPS35-Related Parkinson Disease
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. Recommended Surveillance for Individuals with VPS35-Related Parkinson Disease
No clinical trials have been registered for Parkinson disease 17.
329 publications have been identified in PubMed for Parkinson disease 17. Kisho has analyzed 183 by research type. Research spans Epidemiology / Natural History (26%), Review / Meta-Analysis (25%), and Basic Science / Preclinical (23%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 48 | 26% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 8:40 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Parkinson disease 17
1 |
Postural instability |
VPS35-related Parkinson disease (PARK-VPS35) is indistinguishable from Parkinson disease of unknown cause representing a simplex case (also referred to as "sporadic" Parkinson disease; see ). PARK-VPS35 is characterized by cardinal manifestations of typical parkinsonism (resting tremor, bradykinesia, rigidity, disturbance of postural reflexes). Similar to simplex Parkinson disease of unknown cause, non-motor symptoms also occur; however, neuropsychiatric disturbances and dementia are less common. Atypical features are also of lower frequency compared to simplex Parkinson disease of unknown cause. Disturbances of postural reflexes, autonomic manifestations, and sleep disorders occur at a similar rate to simplex Parkinson disease of unknown cause. PARK-VPS35 manifestations may be variable among affected individuals within the same family. To date, approximately 150 individuals with PARK-VPS35 have been identified [; ; ; ; ; ; ; ; ; ; Dulski et al, unpublished data]. Table 2. Select Features of VPS35-Related Parkinson Disease
Feature | % of Persons w/Feature1 | Comment |
|---|---|---|
Resting tremor | 98% | — |
Bradykinesia | 96% | — |
Rigidity | 95% | — |
Disturbance of postural reflexes | 67% | — |
Neuropsychiatric manifestations | 68% | — |
Cognitive issues | 42% | Learning difficulties, mild cognitive impairment, dementia |
Good response to levodopa | 80% | — |
Motor fluctuations | 85% | — |
Dyskinesia | 80% | — |
Dystonia | 32% | — |
Autonomic manifestations | 75% | Age of onset. Median age of onset was 52 years (interquartile range [IQR]: 45-61) in a group of 67 affected individuals , and 48 years (IQR: 44-56) in a group of 23 affected individuals . Parkinson subtype. The motor manifestations do not differ from simplex Parkinson disease of unknown cause. |
Source: GeneReviews — "VPS35-Related Parkinson Disease"
The differential diagnosis of PARK-VPS35 includes other types of hereditary adult-onset Parkinson disease and simplex Parkinson disease of unknown cause (referred to as sporadic or idiopathic Parkinson disease in the literature; see ). Apart from a younger age at onset and typically slower progression, the phenotype of PARK-VPS35 is clinically indistinguishable from that of simplex Parkinson disease of unknown cause (average onset is age 60 years). Thus, the differential diagnosis of PARK-VPS35 is the same as it is for Parkinson disease in general (see Parkinson Disease Overview). In addition, an extensive list of differential diagnoses of familial parkinsonism can be found in and Dulski et al [unpublished data]. Table 3a. Genes Associated with Early-Onset Adult Parkinson Disease (Age 20-50 Years) and Late-Onset Adult Parkinson Disease (Age 50 Years)
Gene1 | PD Designation2 | MOI | % of Adult PD | Comments |
|---|---|---|---|---|
GBA1 (GBA)3 | PARK-GBA (OMIM 606463) | AD | 3%-7%(20% in AJ ancestry) | Onset age may be 50 yrs.; Higher likelihood of cognitive impairment atypical motor findings; Faster progression; Assoc w/dementia w/Lewy bodies; Variable penetrance dependent on age, variant, ethnicity; Consider if family history of Gaucher disease. |
LRRK2 | PARK-LRRK2(See LRRK2 PD.) | AD | 1%-2%(13%-30% in AJ ancestry; 41% in African Berber ancestry) | Classic manifestations w/less non-motor involvement |
Variable penetrance dependent on age, variant, ethnicity PARK7(DJ1) | PARK-DJ1 (OMIM 606324) | AR | Rare | Phenotype similar to PARK-Parkin; ID /or seizures occasionally; Risk to heterozygotes unknown |
PINK1 | PARK-PINK1(See PINK1 Type of Young-Onset PD.) | AR | Rare(3.7% of early-onset adult PD) | Phenotype similar to PARK-Parkin; Non-motor manifestations (incl psychiatric features) more common; Heterozygotes may have PD risk. |
PRKN | PARK-Parkin(See Parkin Type of Early-Onset PD.) | AR | 1%(4.6%-10.5% of early-onset adult PD) | Slow progression; Can have lower-limb dystonia, dyskinesias, hyperreflexia; Mild non-motor manifestations; Heterozygotes may have PD risk. |
SNCA | PARK-SNCA (OMIM 168601, 605543) | AD | Rare | Onset age may be 50 yrs.; Cognitive psychiatric features more likely |
VPS13C | PARK-VPS13C (OMIM 616840) | AR | Rare | Early-onset PD w/very rapid progression; Truncating variants cause severe disease. AD = autosomal dominant; AJ = Ashkenazi Jewish; AR = autosomal recessive; ID = intellectual disability; MOI = mode of inheritance; PD = Parkinson disease 1. Genes are listed in alphabetic order. 2. |
Source: GeneReviews — "VPS35-Related Parkinson Disease"
Biomarker and diagnostic research for Parkinson disease 17 has been reported in the published literature.
System/Concern |
|---|
Evaluation |
|---|
Comment |
|---|
Neurologic | Neurologic eval | In particular, assessment of movement disorder(s) Physical medicine rehab/ PT OT eval |
Psychiatric | Neuropsychiatric eval | To assess for psychiatric manifestations (e.g., mood disorders, hallucinations, delusions, anxiety, sleep disorders) |
Cognition | Cognitive assessment | Autonomic dysfunction |
Genetic counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of PARK-VPS35 to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with VPS35-Related Parkinson Disease Manifestation/Concern | Treatment | Considerations/Other Neurologic |
Dementia | Treatment w/cholinesterase inhibitor (rivastigmine) should be considered. | — |
Orthostasis | Consider treatment w/droxidopa, midodrine, fludrocortisone. | — |
Constipation | Symptomatic treatment | To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. |
Source: GeneReviews — "VPS35-Related Parkinson Disease"
Neuroleptic drugs may increase the severity of parkinsonism in individuals with PARK-VPS35 (as in Parkinson disease in general). In general, atypical neuroleptics are less likely to exacerbate parkinsonism than typical neuroleptics; in particular clozapine, quetiapine, or pimavanserin are considered well tolerated and effective in Parkinson disease. Other drugs that may induce or exacerbate parkinsonism include but are not limited to antidepressants, calcium channel blockers, valproate, lithium, and amiodarone . Ergot-derived dopaminergic drugs should be discontinued if fibrotic heart-valve changes are identified .
Source: GeneReviews — "VPS35-Related Parkinson Disease"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "VPS35-Related Parkinson Disease"
View trials for Parkinson disease 17
Evaluation |
|---|
Frequency |
|---|
Neurologic | Neurologic eval to assess motor non-motor symptoms treatment effects | Every 6-12 mos or as needed |
Psychiatric | Neuropsychiatric eval | In those w/mood disorder or psychotic symptoms, or as needed |
Cognition | Cognitive assessment | In those w/cognitive impairments or neuropsychiatric symptoms (psychosis), or as needed Autonomic dysfunction |
Cardiac manifestations1 | Echocardiogram to assess for fibrotic heart-valve changes | As needed in those treated w/ergot-derived dopaminergic drugs Family support resources |
Source: GeneReviews — "VPS35-Related Parkinson Disease"
Research summaries
46 |
25% |
Laboratory research | 43 | 23% |
Clinical study results | 23 | 13% |
Testing and diagnosis research | 12 | 7% |
New treatment approaches | 5 | 3% |
Other research | 3 | 2% |
Patient case studies | 3 | 2% |
Liu T (2026). [PMID: 41731626](https://pubmed.ncbi.nlm.nih.gov/41731626/). *Hum Brain Mapp*. [Epidemiology / Natural History]
Yan R (2026). [PMID: 41766856](https://pubmed.ncbi.nlm.nih.gov/41766856/). *Front Immunol*. [Review / Meta-Analysis]
Aslan FS (2026). [PMID: 41904982](https://pubmed.ncbi.nlm.nih.gov/41904982/). *ACS Chem Neurosci*. [Review / Meta-Analysis]
He R (2026). [PMID: 42071793](https://pubmed.ncbi.nlm.nih.gov/42071793/). *Medicine (Baltimore)*. [Epidemiology / Natural History]
Karakose S (2026). [PMID: 41172923](https://pubmed.ncbi.nlm.nih.gov/41172923/). *Arch Gerontol Geriatr*. [Epidemiology / Natural History]
Rosado-Martins F (2026). [PMID: 40854008](https://pubmed.ncbi.nlm.nih.gov/40854008/). *Mov Disord Clin Pract*. [Review / Meta-Analysis]
Tian J (2026). [PMID: 41727462](https://pubmed.ncbi.nlm.nih.gov/41727462/). *Front Immunol*. [Review / Meta-Analysis]
Alcalay RN (2026). [PMID: 42085646](https://pubmed.ncbi.nlm.nih.gov/42085646/). *Neurology*. [Epidemiology / Natural History]
Shao Y (2026). [PMID: 41912482](https://pubmed.ncbi.nlm.nih.gov/41912482/). *Signal Transduct Target Ther*. [Basic Science / Preclinical]
Lei Y (2026). [PMID: 41505625](https://pubmed.ncbi.nlm.nih.gov/41505625/). *ACS Chem Neurosci*. [Basic Science / Preclinical]